Artículo
Engineering tumor hypersusceptibility to checkpoint immunotherapy
Fecha de publicación:
04/09/2017
Editorial:
Cell Press
Revista:
Trends in Cancer
ISSN:
2405-8033
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
The immune checkpoint blockerpembrolizumab(Keytruda)hasproven successful in treating solidtumors harboring a DNA mismatchrepair (MMR) deficiency. We showthat it is possible to generate adrug-promoted phenotype mim-icking the MMR deficiency in solidtumors, and thereby to engineer ageneric hypersusceptibility to Key-truda through drug-induced meta-bolic stress on DNA synthesis. Thepotential of such drug–Keytrudacombinations as universal treat-ments for solid tumors deserves clinical evaluation.
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(INQUISUR)
Articulos de INST.DE QUIMICA DEL SUR
Articulos de INST.DE QUIMICA DEL SUR
Citación
Fernandez, Ariel; Engineering tumor hypersusceptibility to checkpoint immunotherapy; Cell Press; Trends in Cancer; 3; 10; 4-9-2017; 675-677
Compartir
Altmétricas